Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499457 | 0.96 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4PTGS2 | |
| SCHEMBL6499702 | 0.81 | SLC6A3 (0.74) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL6498616 | 0.81 | PTGS2 (0.53) | SLC6A2SLC6A3SLC6A4PTGS2PTGS1 | |
| SCHEMBL6503781 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4PTGS2 | |
| SCHEMBL6503784 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4PTGS2 | |
| SCHEMBL21335107 | 0.80 | SLC6A3 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL6999838 | 0.80 | SLC6A3 (0.85) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL6488184 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4PTGS2PTGS1 | |
| SCHEMBL6489462 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4PTGS2PTGS1 | |
| SCHEMBL6492770 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SLC6A2 1801/4885SLC6A3 3942/4885SLC6A4 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.